Evidence map›Paper›PMID 40867645›Full record

ReviewBiomolecules2025

Enhancement of Protein-Protein Interactions by Destabilizing Mutations Revealed by HDX-MS.

Yoshitomo Hamuro, Anthony Armstrong, Jeffrey Branson, Sheng-Jiun Wu, Richard Y-C Huang, Steven Jacobs

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Cancer-associated TRF1 mutations alter PARP1 interaction dynamics: an in silico study.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yoshitomo HamuroJohnson and Johnson Innovative Medicine, 1400 McKean Road, Spring House, PA 19477, USA.ORCID 0000-0001-8564-4718
Anthony ArmstrongJohnson and Johnson Innovative Medicine, 1400 McKean Road, Spring House, PA 19477, USA.
Jeffrey BransonJohnson and Johnson Innovative Medicine, 1400 McKean Road, Spring House, PA 19477, USA.
Sheng-Jiun WuJohnson and Johnson Innovative Medicine, 1400 McKean Road, Spring House, PA 19477, USA.ORCID 0000-0002-5891-6252
Richard Y-C HuangJohnson and Johnson Innovative Medicine, 1400 McKean Road, Spring House, PA 19477, USA.ORCID 0000-0002-7172-110X
Steven JacobsJohnson and Johnson Innovative Medicine, 1400 McKean Road, Spring House, PA 19477, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enhancing protein-protein interactions is a key therapeutic strategy to ensure effective protein function in terms of pharmacokinetics and pharmacodynamics and can be accomplished with methods like directed evolution or rationale design. Previously, two papers suggested the possible enhancement of protein-protein binding affinity via destabilizing mutations. This paper reviews the results of the previous literature and adds new data to show the generality of the strategy that destabilizing the unbound protein without significantly changing the free energy of the complex can enhance protein-protein interactions for therapeutic benefit. The first example presented is that of a variant of human growth hormone (hGHv) containing 15 mutations that improve the binding to the hGH binding protein (hGHbp) by 400-fold while retaining full biological activity. The second example is that of the YTE mutations (M252Y/S354T/T256E) in the Fc region of a monoclonal antibody (mAb). The YTE mutations improve the binding of the mAb to FcRn at pH 6.0 10-fold, resulting in elongated serum half-life of the mAb. In both cases, (i) chemical titration or differential scanning calorimetry (DSC) showed the mutations destabilize the unbound mutant proteins, (ii) isothermal titration calorimetry (ITC) showed extremely favorable enthalpy (ΔH) and unfavorable entropy (ΔS) upon binding to their respective target molecule compared with the wildtype, and (iii) hydrogen/deuterium exchange-mass spectrometry (HDX-MS) revealed that these mutations increase the free energy of unbound mutant protein without significantly affecting the free energy of the bound state, resulting in an enhancement to the binding affinities. The third example presented is that of the JAWA mutations (T437R/K248E) also located in the Fc region of a mAb. The JAWA mutations facilitate antibody multimerization upon binding to cell surface antigens, allowing for enhanced agonism and effector functions. Both DSC and HDX-MS showed that the JAWA mutations destabilize the unbound Fc, although the complex was not characterized due to weak binding. Enhancement of protein-protein interactions through incorporation of mutations that increase the free energy of a protein's unbound state represents an alternative route to decreasing the protein-protein complex free energy through optimization of the binding interface.

Indexed as

Human Growth HormoneMutationAntibodies, MonoclonalHumansHydrogen Deuterium Exchange-Mass SpectrometryProtein BindingProtein StabilityThermodynamicsAntibodies, MonoclonalHuman Growth Hormonebackbone amidedestabilizationhydrogen/deuterium exchangemass spectrometrymutationprotein–protein interaction

Identifiers

PMID40867645
PMCPMC12384571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.